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Abstract.  Arterial proteoglycans have been implicated 
in several  important physiological processes ranging 
from lipid metabolism to regulation of smooth muscle 
cell growth. Vascular  smooth muscle (VSM)  cells are 
the major producers of proteoglycans in the medial 
layer of blood vessels.  To study functional conse- 
quences of alterations in VSM proteoglycan metabo- 
lism we used 4-methylumbelliferyl-~-D-xyloside  to in- 
hibit proteoglycan synthesis in primary and early 
passage cultures of rat aortic smooth muscle cells. 
Biochemical analysis of cultures labeled with 35SO, 
showed the drug inhibited synthesis of different classes 
of proteoglycans by 50 to 62 %.  Inhibition of pro- 
teoglycan synthesis resulted in reduced accumulation 
of extracellular matrix, as shown by immunofluores- 
cent staining with antibodies to chondroitin sulfate, 
fibronectin, thrombospondin, and laminin. There was 
also an inhibition of postconfluent (multilayered) 
growth of the smooth muscle cells, and a change in 
the morphology of the cells, with no apparent effect 
on subconfluent growth. In addition, in drug-treated 
cells there was a reduction in the number of cytoskele- 
tal filaments that contained ot-actin,  the actin subtype 
synthesized by differentiated VSM cells. This occurred 
even though the total  content of c~-actin in the cells 
was not reduced. The effects of the inhibitor on 
growth and morphology could be reversed by switch- 
ing the cultures to normal medium and could be 
prevented by growing the cells on preformed VSM  ex- 
tracellular  matrix. These observations suggest the vas- 
cular extracellular matrix may play a role in regulating 
the growth and differentiation of smooth muscle cells. 
T 
HE extracellular  matrix  (ECM)'  was once  regarded 
as an inert substance whose only function was to pro- 
vide  mechanical  stability  to  tissues.  Recent  studies 
have indicated, however, that the ECM is involved in a num- 
ber of cell  functions  such as adhesion,  migration,  prolif- 
eration,  and regulation of gene expression (2,  15, 23, 46). 
Several ECM  components  and  their  receptors  have been 
identified and purified which has allowed for an examination 
of ECM function at the molecular level (10, 21, 41). 
Proteoglycans  are  major components  of ECM,  but  de- 
tailed knowledge of the specific functions of these molecules 
is still lacking. Evidence suggests proteoglycans play impor- 
tant roles in cell proliferation (11, 14, 34), cell matrix adhe- 
sion (8, 9, 26, 28, 29, 37), and overall ECM architecture (19, 
44).  One interesting and potentially important property  of 
proteoglycans is their ability to bind to other matrix compo- 
nents such as fibronectin, laminin, and thrombospondin (13, 
19, 30, 36, 37, 46). 
Vascular smooth muscle (VSM) cells are the major pro- 
ducers of proteoglycans in the arterial wall (44). VSM cells 
1. Abbreviations used in this paper: /3-D-xyloside, 4-methylumbelliferyl-~- 
D-xyloside; CHAPS, 3-([3-cholamidopropyl)dimethyl-ammonio]l-propane 
sulfonate); ECM, extracellular matrix; VSM, vascular smooth muscle. 
grown in tissue culture have been a useful model to study 
proteoglycan synthesis. These  studies have shown that the 
bulk  of the  proteoglycans  synthesized  by  VSM  cells  are 
chondroitin sulfate and dermatan sulfate proteoglycans that 
are secreted into the culture medium (6, 45) to be incorpo- 
rated into the extracellular matrix produced by these cells. 
VSM cells also synthesize lesser amounts of cell-associated 
heparan sulfate (6,  14). Recent studies have revealed VSM 
cells synthesize at least two types of cell associated heparan 
sulfate proteoglycan: one that appears to be a basement mem- 
brane proteoglycan, and a second type that is a hydrophobic 
cell surface proteoglycan (Hamati, H., and D. Carey, manu- 
script submitted for publication). 
Previous  studies have implicated VSM proteoglycans in 
the pathogenesis of cardiovascular diseases such as arthero- 
sclerosis (1, 42, 43). There is increased accumulation ofpro- 
teoglycans in the walls of artherosclerotic  vessels (43). Ex- 
periments in vitro have shown that proteoglycans can bind 
low density  lipoproteins  and may allow them to be taken 
up by smooth muscle cells and macrophages (1, 22). Also, 
there is evidence that glycosaminoglycans may regulate the 
proliferation of VSM cells.  Commercial  heparin  (4),  syn- 
thetic heparin oligosaccharides (5), and heparan sulfate iso- 
lated from VSM cell cultures  (14) are potent inhibitors of 
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teoglycans, possibly those made by VSM cells, are involved 
in  keeping VSM  cell proliferation low in normal healthy 
vessels. 
In light of their potential importance we have initiated an 
investigation of  the properties and functions of VSM cell pro- 
teoglycans. As one approach toward studying proteoglycan 
function we have used the specific inhibitor of proteoglycan 
synthesis,  4-methylumbelliferyl-/~-D-xyloside  (~-D-xyloside) 
to  determine what functional consequences could be ob- 
served in VSM cell cultures in which proteoglycan synthesis 
was inhibited. In this paper we present evidence that inhibi- 
tion of proteoglycan synthesis has no effect on the subcon- 
fluent growth of VSM cells, but it substantially inhibits the 
deposition of extracellular matrix and the postconfluent (mul- 
tilayered) growth and differentiation of the cells. Effects of 
proteoglycan synthesis inhibition can be prevented by grow- 
ing the cells on preformed VSM cell extracellular matrix. 
Materials and Methods 
Cell Cultures 
VSM cells were obtained from medial strips dissected from aortas of male 
Sprague-Dawley rats (Charles River Breeding Laboratories, Inc., Wilming- 
ton, MA). The medial strips were dispersed to single cell suspensions by 
digestion with enzymes. The strips were placed in a solution of 0.3% col- 
lagenase (type CLS III; Worthington Biochemical Corp., Freehold, NJ) in 
DME (5 ml/4 aortas) and incubated in a humidified atmosphere containing 
5% CO2 with gentle rotation at 37°C for 1 h. The collagenase solution was 
removed and 0.1% elastase (Sigma Chemical Co., St. Louis, MO) in DME 
(3 ml/4 aortas) was added to the remaining tissue and incubation was con- 
tinued for another hour. Finally, 0.3 % collagenase (4 ml/4 aortas) was added 
to the elastase suspension and incubation was continued for one more hour. 
The dispersed cells were  pelleted by  centrifugation and  resuspended in 
DME supplemented with 10 % FCS (DME-FCS). The cells were seeded at 
50,000 cells/cm  2 in plastic tissue culture dishes or glass coverslips. Cells 
were subcultured by trypsinization with 0.125 % trypsin in Hank's balanced 
salt solution (HBSS)  without Ca  ++ and Mg  +÷.  Cell culture supplies and 
media were purchased from Gibco Laboratories (Grand Island, NY). For 
the experiments reported here, cells were used as primary cultures or in the 
first or second passage. 
Proteoglycan Analysis 
To assess the effects of ~-o-xyloside on proteoglycan synthesis VSM cells 
were grown for 4 d  in DME-FCS containing either no inhibitor or 1 mM 
~-o-xyloside and then incubated in Ham's F12 medium with 10%  FCS and 
100/~Ci/ml 35SO4 (carrier-free sulfuric acid; ICN Radiochemicals, Irvine, 
CA) for 24 h in the presence or absence of the inhibitor. At the end of the 
labeling period the media were removed and dialyzed to remove unincorpo- 
rated isotope.  The cells were then extracted sequentially with 2%  3-([3- 
cholamidopropyl] dimethyl-ammonio)l-propanesulfonate  (CHAPS), 0.1 M 
Tris-HCl,  pH  7.5,  and 2%  SDS,  0.1  M  Tris-HC1, pH 7.5,  to  solubilize 
membrane-associated and  ECM  proteoglycans, respectively.  Aliquots of 
media and cell extracts were subjected to gel permeation HPLC on a TSK- 
4000SW column (Beckman Instruments, Inc., Palo Alto, CA) eluted with 
0.1%  SDS, 0.1  M  Tris-HCl, pH 7.5,  at a flow rate of 1 ml/min. Fractions 
of 0.5 ml were collected and radioactivity was counted by liquid scintillation 
counting to quantitate 35SO4 incorporation into proteoglycans and glycos- 
aminoglycans. 
The proteoglycans were identified and characterized by their susceptibil- 
ity  to  various  chemical  and  enzymatic  digestions.  Glycosaminoglycan 
chains were  released  from proteoglycans by  mild alkaline hydrolysis in 
0.2 M NaOH at room temperature for 16-18 h. Nitrous acid hydrolysis was 
done in 0.25 M  NaNO2, 0.18 M  acetic acid at room temperature for 2 h. 
Digestions with chondroitinases ABC and AC were carried out in 0.2 M 
Tris-0.2 M sodium acetate, pH 7.3, at 37°C for 4 h. Digestion products were 
analyzed by gel permeation HPLC on a TSK-40OOSW  column. 
lmmunofluorescent  Staining 
Cells to be immunostained were grown on glass coverslips. The medium 
was removed and the coverslips were rinsed with PBS (0.15 M NaCI, 0.05 
M sodium phosphate, pH 7.5). For staining of ECM proteins the cells were 
incubated with primary antibodies for 1 h at 4°C before fixation. After rins- 
ing the cells were fxed with 3 % paraformaldehyde for 30 rain at room tem- 
perature.  For staining of intracellular proteins the cells were fixed with 
paraformaldehyde and then permeabilized with ice-cold acetone or 0.05% 
Triton X-100 for 30 s. The cells were rinsed with Blotto (20 mM Tris-HCl, 
pH 7.4, 0.1 M NaCI, 5 % Carnation nonfat dry milk) (24) and then incubated 
for 1 h at room temperature with primary antibodies diluted in Blotto. After 
rinsing with Blotto, the cells were incubated with the appropriate affinity- 
purified  fluorescein-conjugated  secondary  antibodies  (Sigma  Chemical 
Co.) diluted in Blotto for 1 h. The coverslips were rinsed with Blotto and 
mounted on glass slides. Fluorescein was visualized using a Nikon Diaphot 
inverted microscope equipped for epifluorescence. 
Mouse monoclonal antibodies to vimentin and chondroitin sultate were 
purchased from ICN  Immunologicals (Irvine,  CA).  The latter antibody 
reacts with chondroitin-4 and chondroitin-6-sulfate glycosaminoglycans  but 
not with dermatan or heparan sulfate. Mouse monoclonal anti-smooth mus- 
cle  c~-actin,  anti-thrombospondin, and anti-fibronectin as  well  as anti- 
fibronectin goat antiserum were purchased from Sigma Chemical Co. Anti- 
laminin rabbit antiserum was produced in this laboratory (3). 
Growth Assays 
To examine effects of ~-D-xyloside on VSM cell growth, cells were tryp- 
sinized and seeded at a density of 50,000 cells/era  2 in four-well Nunc mul- 
tidishes (Thomas Scientific, Philadelphia, PA) with 2 cm  2 growth area per 
well.  The cells were grown in DME-FCS in the presence or absence of 
1 mM/3-o-xyloside. The cells in quadruplicate wells were counted 24-36 h 
after seeding and every few days for up to 10 d. For counting, the cells were 
released from the plates by trypsinization and counted electronically using 
a  Coulter Counter Model ZM (Coulter Electronics Inc., Hialeah, FL). 
To examine effects of secreted glycosaminoglycans on VSM cell growth 
the  glycosaminoglycans were  purified  from  conditioned  media  of /3-D- 
xyloside-treated cells. Conditioned medium was collected over three con- 
secutive 24-h periods from VSM cells growing in two 100-mm dishes, each 
containing "~1.5  ×  107 cells.  Radiolabeled medium glycosaminoglycans 
from  /3-o-xyloside-treated cells  were  added  as  tracer.  The conditioned 
medium was dialyzed vs 0.1 M Tris-HCI, pH 7.5, and applied to 0.75  ×  7.5 
cm DEAE-5PW column (Beckman Instruments Inc.) and eluted with a lin- 
ear gradient of 0-1 M NaC1 containing 0.1 M Tris-HCl, pH 7.5. The frac- 
tions containing the radiolabeled glycosaminoglycans  (which eluted at a salt 
concentration of "~0.5 M) were pooled, dialyzed extensively vs. H20, and 
lyophilized. The dried glycosaminoglycans  were dissolved in DME-FCS at 
approximately four times their concentration in the original conditioned 
medium and used to  feed cells growing in  four-well plates as described 
above. 
To assess effects of exogenous ECM on cell growth,  VSM cells were 
seeded at a  density of 50,000 cells/era  2 on either plastic or ECM-coated 
dishes (see below) and grown in DME-FCS containing 1 mM B-o-xyloside. 
To prepare VSM cell ECM, postconfluent cultures were extracted with 
2% deoxycholate, 0.1 M  Tris-HCl, pH 7.5,  for 20 min at 4°C. The dishes 
were washed extensively with ice-cold PBS and then used immediately for 
immunostaining or as a  substrate for cell growth. 
Gel Electrophoresis and lmmunoblotting 
Gel electrophoresis and immunoblotting were used to estimate the amount 
of c¢-actin in control and/3-D-xyloside-treated cells. Groups of cultures were 
trypsinized and counted with a Coulter counter (to determine total cell num- 
bers) or solubilized with 2% SDS, 0.0625 M Tris-HC1, pH 6.8, 5% 2-mer- 
captoethanol, 10% glycerol (for electrophoresis). Extracts from equal num- 
bers of control and drug-treated cells were loaded onto 10% polyacrylamide 
slab gels prepared  according to  Laemmli (27).  After electrophoresis the 
resolved  proteins  were  electrophoretically  transferred  to  nitrocellulose 
(70 V, 40 rain), incubated in Blotto at room temperature for  1 h to block 
nonspecific binding, and stained with anti-ot-actin antibody (1:400 dilution 
in Blotto).  The bound antibody was visualized with afffinity-purified  per- 
oxidase-conjugated goat  anti-mouse  IgG  (Bio-Rad  Laboratories,  Rich- 
mond, CA) using 4-chloro-l-naphthol as substrate. 
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Figure 1.  Gel permeation chromatography of proteoglycans and 
glycosaminoglycans of control and ~-o-xyloside-treated  cultures. 
Cells were grown in DME-FCS for 5 d without (A, C, and E) or 
with (B, D, and F) 1 mM/3-D-xyloside  and labeled for the last 24 h 
with 35SO4. After labeling the medium was removed and the cell 
layers  were  extracted  sequentially  with  buffers containing  2% 
CHAPS and 2% SDS. Aliquots of the medium (A and B), CHAPS 
extracts (C and D), and SDS extracts (E and F) were subjected to 
gel permeation chromatography on a TSK-4000SW column. 
Results 
Effects of  /Y-o-Xyloside on VSM Proteoglycan Synthesis 
To study the effects of ~-D-xyloside on proteoglycan synthe- 
sis aortic VSM cells were grown in plastic dishes in DME- 
FCS with or without 1 mM/3-D-xyloside for 5 d. During the 
last 24 h 35SO4 was added to the medium to label the pro- 
teoglycans. At the end of the labeling the medium was re- 
moved and the cells were extracted with 2% CHAPS (to sol- 
ubilize membrane-associated proteoglycans) followed by 2 % 
SDS (to solubilize ECM proteoglycans). To assess 3~SO4 in- 
corporation into proteoglycans aliquots of the medium, non- 
ionic detergent extracts, and SDS extracts were subjected to 
gel permeation chromatography on a TSK-4,000 SW column. 
Column profiles from control cultures are shown in Fig. 
1 (A, C, and E). As shown in Fig.  1 A the medium of control 
cultures contained a large radioactive peak that was eluted 
at fraction 13, a smaller shoulder in fractions 16-20, and a 
small peak at fraction 23. Chemical and enzymatic analysis 
revealed that the first peak was mostly chondroitin sulfate 
and  dermatan  sulfate  proteoglycans,  whereas  the  smaller 
shoulder was primarily free glycosaminoglycan chains (not 
shown). The small peak appearing at fraction 23 was unin- 
corporated 35SO4. The elution profile of the CHAPS extract 
of the control cells showed a major peak that was eluted at 
fractions 10 and 11 (Fig. 1 C). We have shown that this mate- 
rial is a hydrophobic cell surface heparan sulfate, proteogly- 
can (Hamati,  H.,  and D.  Carey, manuscript submitted for 
publication). The elution profile of SDS solubilized material 
from control cells (Fig.  1 E) showed a major peak that was 
eluted at fraction 10.  This peak contains basement mostly 
membrane heparan  sulfate proteoglycans plus chondroitin 
sulfate proteoglycans that have been incorporated into ECM 
(Hamati, H., and D. Carey, manuscript submitted for publi- 
cation). 
Column profiles from cultures grown for 5 d in medium 
containing/3-D-xyloside are also shown in Fig.  1 (B, D, and 
F).  The amount of 34SO4-1abeled proteoglycans appearing 
in the medium of/3-D-xyloside-treated cells was reduced to 
26%  of the control  value,  while the  radioactivity in  the 
glycosaminoglycan peak was increased more than threefold 
(Fig. 1 B, Table I). As shown by results presented below, ~D- 
xyloside-treated cultures contain  fewer cells than  control 
cultures.  When the 35SO4 incorporation data were normal- 
ized  to  cell  numbers,  incorporation  of SO4  into  culture 
medium  proteoglycans  of ~-o-xyloside-treated cells  was 
found to be reduced to 38%  of the control value, whereas 
35SO4 incorporation  into  the  medium  glycosaminoglycans 
was increased by fivefold (Table I). The column profiles from 
CHAPS and SDS extracts of ~-o-xyloside-treated cultures 
also showed a decrease in the amounts of  heparan sulfate pro- 
teoglycans relative to the control cultures (Fig. 1, D and F). 
Quantitation  revealed  that  SO4  incorporation  per  culture 
into proteoglycans was reduced to 33 and 35 % of the control, 
or 48 and 50% of control when normalized to cell number 
(Table I). Thus, ~D-xyloside treatment inhibited synthesis of 
secreted chondroitin and dermatan sulfate proteoglycans and 
to a lesser extent, cell-associated heparan sulfate proteogly- 
cans. While ~-D-xyloside treatment resulted in a large stimu- 
lation of glycosasminoglycan synthesis these glycosamino- 
glycans were found exclusively in the culture medium and 
did not become associated with the cells. 
/?-o-Xyloside Inhibits ECM Protein Deposition 
in VSM Cell Cultures 
In other studies inhibition of proteoglycan synthesis resulted 
in a decrease in the deposition of ECM (3, 31). We used in- 
direct immunofluorescence staining with specific antibodies 
Table L Effect of  /Y-o-Xyloside  on 35S04 Incorporation 
into Proteoglycans and Glycosaminoglycan Synthesis 
cpm/culture  cpm/lO  s cells 
Species  -xyl  +xyl  +/-  -xyl  +xyl  +/- 
Medium 
Proteoglycans  230,820  61,164  0.26  40,200  15,400  0.38 
Glycosamino- 
glycans  279,876  954,576  3.4  48,800  241,800  5.0 
CHAPS-extracted  104,160  34,110  0.33  18,100  8,600  0.48 
proteoglycans 
SDS-extracted  98,490  33,990  0.35  17,200  8,600  0.50 
proteoglycans 
VSM cells were grown in plastic dishes in DME-FCS without or with  I mM 
13-D-xyloside for 5 d. During the last 24 h ~5SO4 was present in the medium to 
label  the  proteoglycans.  Parallel  groups of cells were  either harvested for 
biochemical analysis of radiolabeled  proteoglycans, or trypsinized and counted 
to  determine total  cell  numbers. ~5SO4 incorporation  in  proteoglycans and 
glycosaminoglycans  was determined by gel permeation HPLC and liquid scin- 
tillation  counting (see Fig.  I). 
Hamati et al. Proteoglycan Synthesis Inhibition  Effects  on  VSM Behavior  2497 Figure 2. Effects of ~-D-xyloside on accumulation of ECM proteins.  VSM cell cultures were grown in DME-FCS without (A, C, E, and 
G)  or with  (B,  D,  F,  and  H)  1 mM /~-D-xyloside. After 7  d  the cells  were processed  for indirect  immunofluorescent  staining  with 
anti-chondroitin sulfate antibodies  (A and B), anti-fibronectin antibodies  (C and D), anti-laminin antibodies  (E and F), and anti-throm- 
bospondin  antibodies  (G and H).  Fields were photographed  and printed  under identical conditions.  Bar, 100 #m. 
to determine the effect of inhibition of proteoglycan synthesis 
on ECM  protein deposition  in VSM cell  cultures.  Control 
cultures  stained  with  anti-chondroitin  sulfate  antibodies 
showed bright and specific fibrillar staining of the ECM (Fig. 
2  A).  As  shown in Fig.  2  B  staining  by this  antibody was 
nearly abolished by the drug treatment.  Similar results were 
obtained after staining with antibodies to fibronectin, throm- 
bospondin,  and laminin (Fig.  2).  A  decrease in the deposi- 
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Figure 3. Effects  of/3-D-xyioside on VSM cell growth. VSM cells 
were seeded in four-well  plates and grown in DME-FCS without ((3) 
or with (e) 1 mM ~-o-xyloside. Cells were trypsinized and counted 
after 24 h and every few days thereafter. Each point represents the 
mean +  SD of four cultures. 
tion of ECM in/3-o-xyloside-treated cultures was also ob- 
served by transmission electron miscroscopy (not shown). 
These  results  demonstrate  that  inhibition  of proteoglycan 
synthesis leads to a decreased deposition of both proteogly- 
cans and glycoproteins into ECM. 
Effects of  ~-o-Xyloside on VSM Cell Growth 
and Morphology 
To assess the effects of 13-D-xyloside treatment on VSM cell 
growth freshly trypsinized cells were seeded in plastic dishes 
at low density and maintained in DME-FCS with or without 
the drug. Cells were released from the dishes by trypsiniza- 
tion and cell numbers were determined every few days. The 
presence of the drug had no effect on cell attachment mea- 
sured 24 h after seeding or initial (subconfluent) growth rates 
(Fig. 3). In these experiments the ceils became confluent on 
day 4 after plating. As is typical for VSM cells in culture the 
control cells continued to proliferate after they reached con- 
fluence to form multilayers with ceils growing on top of one 
another. This phenomenon can be seen by observing the cells 
with differential interference contrast microscopy (Fig. 4 A). 
In contrast, proliferation of the ~-D-xyloside-treated cells 
stopped when the cells became confluent and cell numbers 
remained nearly constant from day 4 after plating until day 
10. As revealed by differential interference contrast micros- 
copy these cells formed a monolayer and did not exhibit the 
typical multilayered growth (Fig. 4 B). Thus, /3-D-xyloside 
treatment  inhibits  the  postconfluent but  not  subconfluent 
growth of VSM cells. 
In addition to these changes in the pattern of VSM cell 
growth, ~o-xyloside treatment also caused a change in the 
morphology of the VSM cells. As shown in Fig. 5 A, the con- 
trol cells showed the typical spindle shape characteristic of 
these cells. The drug-treated cells, in contrast, were rounded 
or cuboidal in shape (Fig. 5 B). 
These effects of the drug on growth and morphology were 
reversible. When cultures that had been grown for 9 d in the 
presence of 1 mM  /3-D-xyloside  were switched to normal 
medium, within 48 h the cells regained their spindle mor- 
phology and began to proliferate (not shown). In other ex- 
periments we showed that DMSO, which was used as a vehi- 
cle for the drug, and ct-methylxyloside, an inactive xyiose 
derivative, had no effects on the growth or morphology of 
VSM cells (data not shown). 
Effects of  fl-o-Xyloside on VSM Cell Growth Are Not 
Caused by the Increase in Medium 
Glycosaminoglycans 
As shown above, inhibition of proteoglycan synthesis by/3-D- 
xyloside also caused an increase in the amount of glycosami- 
noglycans secreted into the medium. Heparin (a glycosami- 
noglycan related to heparan sulfate) is a potent inhibitor of 
VSM  cell proliferation (4,  5).  To determine whether the 
glycosaminoglycans present in the medium of ~-D-xyloside- 
treated culture were responsible for the inhibition of VSM 
cell growth, we purified the glycosaminoglycans from medi- 
um conditioned by/3-D-xyloside-treated cultures and added 
them to the medium of cells growing in DME-FCS without 
~-D-xyloside. As shown in Table II, there was no detectable 
inhibition of growth caused by addition of the glycosamino- 
glycans. 
Effects of Exogenous ECM 
Another effect of inhibition of proteoglycan synthesis by/3-D- 
xyloside is inhibition of ECM deposition. If the lack of ECM 
is responsible for effects of/3-D-xyloside on VSM growth and 
morphology, it should be possible to prevent these effects by 
providing the cells with exogenous ECM. For these experi- 
ments, VSM-ECM was obtained by growing cells to a high 
density and then removing the cells by extraction with 2 % 
deoxycholate. This treatment does not remove the ECM de- 
posited by the cells as shown by immunofluorescent staining 
with antibodies to chondroitin sulfate, fibronectin (Fig. 6), 
laminin, and basement membrane proteoglycans (not shown). 
That deoxycholate extraction removed the cells was demon- 
strated by lack of staining with anti-vimentin antibodies (not 
shown). 
To  examine  effects  of exogenous  ECM  on  VSM  cell 
growth, cells were seeded on plastic or ECM-coated dishes 
and grown in DME-FCS containing 1 mM/3-D-xyloside for 
7 d. As shown in Table III, the final density of cells grown 
on ECM-coated plates was increased significantly in com- 
parison to cells on plastic (which had formed a  confluent 
monolayer). In addition to this effect on growth, cells grown 
on ECM in the presence of/3-o-xyloside displayed normal 
morphology. Fig. 5 compares the appearance of cells grown 
on plastic without (a) and with (b) 1 mM/3-D-xyloside with 
cells grown on ECM with 1 mM/3-o-xyloside (c). The drug- 
treated cells on ECM were spindle shaped and were indistin- 
guishable from the control cells grown on plastic. 
Effects of  /~-o-Xyloside on ~-Actin Expression 
The results presented above demonstrate that inhibition of 
proteoglycan synthesis affects the growth and morphology of 
Hamati et al.  Proteogtycan  Synthesis Inhibition Effects on  VSM Behavior  2499 Figure 4.  Effects of/~-D-xyloside  on VSM cell multilayered growth. VSM cells were grown in DME-FCS without (a) or with (b) 1 mM 
B-o-xyloside for 5 d. Cells were visualized by differential interference contrast microscopy. The arrow shows a thickened area where the 
VSM cells were beginning to grow on top of one another. 
VSM cells; these effects appear to be due to the lack of ECM 
in these cultures. To determine whether/3-o-xyloside treat- 
ment had any effect on the phenotypic differentiation of the 
VSM cells we examined the appearance of smooth muscle 
specific ct-actin in the cells, a-Actin is the predominant actin 
subtype synthesized by differentiated VSM cells. It has been 
shown that VSM cells in culture stop producing ot-actin when 
they are plated at subconfluent densities and are growing rap- 
idly, but reexpress ct-actin when they become postconfluent 
and  quiescent  (33).  a-Actin  expression was  examined by 
staining  with  a  specific  monoclonal  anti-smooth  muscle 
et-actin antibody. The specificity of the antibody was demon- 
strated by showing that it did not stain rat liver or skeletal 
muscle actin but did stain rat aortic smooth muscle actin on 
Western blots (not shown). 
Immunofluorescent staining of a postconfluent VSM cell 
culture grown for 10 d in DME-FCS is shown in Fig. 7 A. 
The antibody stained thick actin bundles that in most cells 
were arranged in parallel arrays along the long axis of the 
ceils. When cells that had been grown for 10 d in medium 
containing 1 mM B-D-xyloside were stained with this anti- 
body there was essentially no staining of actin bundles (Fig. 
7 B). Some antibody staining could be seen but it was either 
diffusely distributed in  the  cytoplasm or present in  small 
punctate spots throughout the cytoplasm. This effect of B-o- 
xyloside on ot-actin filaments was reversible. Fig.  7  C and 
D  shows anti-ct-actin staining of cells that were grown for 
7  d  in  medium  containing  B-D-xyloside and  switched  to 
medium lacking the drug 3  d  before staining.  These cells 
contained bundles that stained brightly with the ot-actin anti- 
body, and were indistinguishable from the control cultures. 
The  immunofluorescence staining  results  could  be  ex- 
plained if inhibition of proteoglycan synthesis by/3-o-xyloside 
led to inhibition of tx-actin synthesis. To determine whether 
ot-actin synthesis was blocked, extracts of cells were sepa- 
rated on 10 % polyacrylamide gels, transferred to nitrocellu- 
lose, and stained with anti-ot-actin antibody. As  shown in 
Fig. 8, when extracts from equal numbers of  control and/3-D- 
xyloside-treated cells were loaded on the gel, there was no 
visible difference in the amount of a-actin staining.  Thus, 
B-n-xyloside treatment does not appear to alter the synthesis 
of c~-actin, but interferes with its assembly into filaments. 
Discussion 
The  vascular  wall  is  enriched  in  connective tissue  (44). 
Previous studies have shown that a major component of this 
ECM is proteoglycans synthesized by VSM cells (1, 6, 42, 43, 
44, 45). In the studies reported here we used/~-o-xyloside, 
a specific inhibitor of proteoglycan synthesis, to examine the 
effects by inhibition of proteoglycan synthesis on the be- 
havior of cultured VSM cells. Biochemical analysis showed 
that 1 mM/3-o-xyloside inhibited proteoglycan synthesis by 
50-62 %, depending on the class of proteoglycan, and stimu- 
lated  glycosaminoglycan  synthesis  fivefold.  Inhibition  of 
proteoglycan synthesis was also confirmed by immunofluo- 
rescent staining of cultures with anti-chondroitin sulfate an- 
tibodies. These observations are consistent with the mode of 
The Journal of Cell Biology, Volume  108,  1989  2500 Figure 5.  Effects of/~-o-xyloside on VSM cell morphology. VSM cells were grown in DME-FCS for 7 d on plastic (a and b) or ECM-coated 
(c) dishes in the absence  (a) or presence  (b and c) of 1 mM 13-o-xyloside. Cells were visualized by phase  contrast  microscopy. 
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on VSM Cell Proliferation 
Percent 
Additions*  Cells per well:~  control 
None  921,160  _  13,680  100  o 
/3-xyl  GAG  999,720  +_  20,800  109 
* Glycosaminoglycans were partially purified by anion exchange chromatogra- 
ph)' from medium of/3-D-xyloside-treated  cells (fl-xyl GAG) (see Material and 
Methods). 
Cells  were  seeded (5  ×  10  ~ cells/cm-') in  four-well  plates  (2  cm-' growth 
area per well) and grown in DME-FCS with or without the purified glycosami- 
noglycans; after 7 d the cells were counted; the values shown are the mean _+ SD 
of four cultures. 
action of/3-D-xyloside, which is to act as a primer for glycos- 
aminoglycan chain initiation and compete with the core pro- 
tein at the level of the first glycosyltransferase, which adds 
galactose to a xylose residue on the core protein. The drug 
appears to be specific in its action. It has been demonstrated 
by immunological techniques that in chondrocytes /3-D-Xy- 
loside  does  not  affect core  protein  synthesis  (38).  Other 
studies with chondrocytes have shown that/3-D-xyloside has 
only a slight effect on total protein synthesis as measured by 
[3H]serine incorporation (31). 
Our studies indicated that inhibition of proteoglycan syn- 
thesis  had  profound effects on the  phenotypic behavior of 
VSM cells. We observed an inhibition of postconfluent mul- 
tilayered growth of the cells, an alteration of their morphol- 
ogy, and an inhibition of the polymerization of smooth mus- 
cle c~-actin into filaments. These effects appeared to be due 
to decreased deposition of ECM proteins that occurred in 
/3-D-xyloside-treated cultures.  VSM cells grown on exoge- 
nous ECM-coated dishes in/3-D-xyloside containing medium 
exhibited normal morphology and growth characteristics. 
Several observations indicated that the alterations in cell 
behavior observed in this study are not attributable to toxicity 
of the drug.  First,  the extent of attachment of control cells 
Figure 6. Immunostaining of ECM proteinS in cultures before and after removal of the cells by detergent. VSM cells were grown in DME- 
FCS for 7 d. Control cultures (a and c) and cultures from which cells were removed by extraction with 2% deoxycholate (b and d) were 
processed for indii'ect immunofluorescent staining ,~ith anti-chondroitin  sulfate antibodies (a and b) and anti-fibronectin  antibodies (c and 
d).  Fields were photographed  and printed under  identical conditions. 
The Journal of Cell Biology, Volume  108, 1989  2502 Table IlL Effect of  Exogenous ECM on 
Postconfluent Proliferation of VSM Cells Grown 
in the Presence of  l?-o-Xyloside 
Percent 
Substrate*  Cells  per well~:  increase 
Plastic  278,440  +  5,600  - 
ECM  412,040  +  12,520  48 
* Cells were grown on plastic or ECM-coated dishes for 7 d in DME-FCS plus 
I mM ~-D-xyloside; ECM-coated dishes were prepared as described in Materi- 
als and Methods. 
On  day  7  the  cells  were  trypsinized  and  counted.  The  values  are  means 
_+  SD of four cultures. 
and/3-D-xyloside-treated cells to plastic dishes was identi- 
cal.  Second,  ~o-xyloside  had  no  effect  on  subconfluent 
growth rates of the cells during the first 3  d  after plating. 
Third,  in long term experiments with 13-D-xyloside the cell 
numbers  remained  constant,  indicating  there  was  no  ap- 
preciable cell death even after long exposure to the drug. 
Fourth, effects of/3-D-xyloside on VSM growth and morphol- 
ogy were rapidly reversed by switching to medium lacking 
the drug.  Fifth,  the  effects of/3-D-xyloside on growth and 
morphology  were  prevented  by  growing  cells  on  ECM- 
coated dishes. 
Previous studies have shown that the glycosaminoglycan 
heparin is a potent inhibitor of VSM cell proliferation (4) and 
that the inhibition is caused by a  specific structural variant 
of heparin (5). Our results demonstrated, however, that the 
glycosaminoglycans secreted  by 13-D-xyloside-treated cells 
do not possess this activity. When partially purified glycos- 
aminoglycans from the medium of/3-D-xyloside-treated cul- 
tures were added to cells grown in DME-FCS there was no 
effect on VSM proliferation or morphology. This occurred 
Figure 7. Effects of 13-D-xyloside on ~x-actin distribution.  VSM cells were grown in DME-FCS  for 10 d without (a) or with (b)  1 mM 
/3-o-xyloside or for 7 d in DME-FCS containing  1 mM 13-D-xyloside  followed by 3 d in DME-FCS alone (c and d). On day 10 the cells 
were processed for indirect immunofluorescent staining with smooth muscle-specific  anti-a-actin antibodies. A-C were photographed anc 
printed under identical conditions to demonstrate the difference in staining intensity. D is a high power view to show the fibrillar organization 
of the c~-actin. 
Hamati et al. Proteoglycan  Synthesis Inhibition  Effects  on  VSM Behavior  2503 Figure 8.  Effects  of ~-o-xyloside on the 
ct-actin content of VSM cells. VSM cells 
were grown in DME-FCS for 10 d without 
(lane/) or with (lane 2) 1 mM ~-D-xylo- 
side.  Parallel  cultures  were  trypsinized 
and counted or extracted with 2 % SDS for 
electrophoresis. Extracts from equal num- 
bers of cells were loaded on a 10% poly- 
acrylamide SDS slab gel.  After electro- 
phoresis the proteins were electrophoreti- 
cally  transferred  to  nitrocellulose  and 
stained with anti-a-actin antibody. Num- 
bers and arrows to the left indicate posi- 
tion of migration of molecular mass stan- 
dards (in kilodaltons). 
even when the glycosaminoglycans were added at four times 
their original concentration in the medium of drug-treated 
cells.  In other experiments we have shown that our VSM 
cells are inhibited in their proliferation by commercial hepa- 
rin or heparan sulfate proteoglycan purified from postcon- 
fluent VSM cell cultures (Hamati, H., and D. Carey, manu- 
script submitted for publication). 
Our data indicated that an adequate supply of  proteoglycan 
is necessary for deposition of VSM ECM. Extracellular ma- 
trix assembly is a highly cooperative process (25, 47). Pro- 
teoglycans are essential probably because of their ability to 
form complexes with. other ECM molecules (19).  Some ar- 
terial chondroitin sulfate proteoglycans are able to form large 
supramolecular complexes with hyaluronic acid in a manner 
similar to that of cartilage proteoglycans (42). In that tissue 
a specific region of the chondroitin sulfate proteoglycan core 
protein binds to hyaluronic acid, and the binding is stabilized 
by a glycoprotein called link protein (17). The large (Mr  = 
10  s) highly hydrated aggregates are important in determin- 
ing the mechanical properties of cartilage and presumably 
the arterial  wall.  Other proteoglycans, especially heparan 
sulfate proteoglycans, bind via their glycosaminoglycan side 
chains to ECM proteins such as fibronectin, laminin, colla- 
gen, and thrombospondin (13, 19, 30,  32, 36,  39). Because 
of their multiple side chains the proteoglycans serve as mul- 
tivalent cross-linkers in  the ECM.  Proteoglycans are also 
present on cell surfaces and have been proposed to act as 
receptors for collagen and fibronectin (26,  37). 
Our data also indicated that lack of ECM resulted in al- 
tered morphology of VSM cells and a failure of organization 
of c~-actin filament. A relationship between cytoskeletal or- 
ganization  and  ECM  contact has  been observed in  other 
cells. For example, corneal epithelial cells become columnar 
and  reorganize their actin-rich cortical cytoskeleton when 
placed on collagen or basement membrane (15, 40). These 
observations are consistent with other experiments that have 
shown an apparent linkage between ECM and cytoskeletal 
components mediated by transmembrane receptors. It was 
shown that mesenchymal cells bind to fibronectin via a cell 
surface receptor known as the  140-K complex (7,  10,  21). 
Biochemical and structural studies have suggested that the 
fibronectin receptor is a hydrophobic transmembrane protein 
(41).  Other  studies  have  shown  that  the  140-K  complex 
colocalizes with  fibronectin and  microfilaments (10),  and 
binds to talin (20), a cytoskeletal protein, thus suggesting a 
possible mechanism for fibronectin cytoskeletal interactions. 
Our results demonstrated that inhibition of proteoglycan 
synthesis prevented the characteristic multilayered growth of 
VSM cells.  Results with exogenous ECM suggested this is 
due to the lack of ECM  in drug-treated culture.  Previous 
studies have also demonstrated a relationship between ECM 
and VSM cell growth. It was shown that bovine aortic VSM 
cells grown on corneal endothelial-derived ECM proliferate 
in plasma-containing medium, whereas VSM cells grown on 
plastic proliferate only in the presence of serum (16).  It has 
also been shown that rat VSM cells grown on bovine aortic 
endothelial cell-derived ECM have altered growth rates and 
final  cell  densities  than  cells  grown  on plastic  (18).  The 
mechanism by which cell growth is regulated by ECM is not 
well-understood. One possibility is that the ECM regulates 
growth by altering the shape of the cells.  Changes  in cell 
shape have been shown to alter the growth properties of cells 
(12), although the underlying mechanism is not known. In 
the case of postconfluent VSM cell growth, it is conceivable 
the ECM provides a three-dimensional adhesive scaffold that 
is needed for the cells to grow on the top of one another. 
This relationship between ECM deposition and VSM cell 
growth and differentiation may have relevance to certain car- 
diovascular diseases. VSM proliferation is a major event in 
the development of artherosclerosis. VSM cells and ECM 
are  major  components  of  the  fibrous  plaques  found  in 
atherosclerotic vessels (35). Our data indicate that under cer- 
tain conditions ECM production is obligatory for VSM cell 
proliferation. For these reasons,  further investigations into 
the regulation of ECM production in vascular tissue and the 
mechanism of the effects of ECM on VSM cells are of obvi- 
ous clinical importance. 
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